Nanologica is a Swedish biotechnology company developing nanoporous silica particles for applications within life science. The company is world-leading in controlling the shape, size, and type of porosity of silica particles, creating opportunities to develop unique products. Through the two business areas, Chromatography and Drug Development, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide-based drugs available to more patients in need by providing a purification product that lowers manufacturing cost by being more efficient and lasting longer than competitors. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung. The platform for inhalation is developed to provide new treatment options for patients with severe lung diseases. Nanologica’s stock (NICA) is listed on Nasdaq Main Market. For further information, please visit www.nanologica.com.